Clinical trials: Carcinomas
Locally Advanced Bladder Carcinoma, Metastatic Bladder Carcinoma
An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers
This clinical trial evaluates the impact of an education and navigation support tool (ENST) on patient and caregiver participation in care coordination for bladder cancer that has spread to nearby tissue or lymph nodes (locally…
- Conditions
- Locally Advanced Bladder Carcinoma, Metastatic Bladder Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
- Trial name
- NCT06414317
- Testing
- Assessment of Distress, Consultation Visit, Nutritional Assessment
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Roswell Park Cancer Institute
Head and Neck Squamous Cell Carcinoma
Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)
To assess response rate of docetaxel and S-1 combination in metastatic or recurrent head and neck squamous cell carcinoma
- Trial name
- NCT00805012
- Testing
- docetaxel+CDDP, docetaxel+S-1
- Where
- South Korea
- Volunteers
- 96 people
- Sponsor
- Seoul National University Hospital
Cervical Cancer, Breast Cancer
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or…
- Conditions
- Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC
- Trial name
- NCT05283330
- Testing
- ²¹²Pb-DOTAM-GRPR1
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Orano Med Theranostics, SAS
Advanced Or Metastatic Merkel Cell Carcinoma
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
This Phase 2/3, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the Objective Response Rate (ORR) of IFx-Hu2.0 as an adjunctive therapy to pembrolizumab in adult participants (≥18 years) with…
- Trial name
- NCT06947928
- Testing
- IFx-Hu2.0, Pembrolizumab
- Where
- 18 sites in United States
- Volunteers
- 118 people
- Sponsor
- TuHURA Biosciences, Inc.
Squamous Cell Carcinoma of Head and Neck, Chemotherapy Induced Nausea and Vomiting
A Standardized Intervention to Improve the Management of Chemotherapy-induced Nausea and Vomiting
The goal of this clinical trial is to investigate the effect of a nurse-led standardized intervention on chemotherapy induced nausea and vomiting (CINV) in patients with head and neck squamous cell carcinoma.
- Trial name
- NCT05792228
- Testing
- nurse-led standardized intervention
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Small Cell Lung Cancer (SCLC)
Tislelizumab Combined With Anlotinib and 2-cycles Irinotecan as Second Line Treatment of SCLC
SCLC has short doubling time, high proliferation rate and early widespread metastasis. Most patients with SCLC have hematogenous metastasis. SCLC is highly sensitive to initial chemoradiotherapy, but the recurrence rate is high.
- Trial name
- NCT05027100
- Testing
- Anlotinib Tislelizumab Irinotecan
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Haibo Zhang
Hepatocellular Carcinoma
Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma
The purpose of this study is to assess toxicities of angiogenic peptide vaccine therapy in treating HLA-A*2402 restricted patients with advanced hepatocellular carcinoma.
- Trial name
- NCT01266707
- Testing
- antiangiogenic paptide vaccine
- Where
- Japan
- Volunteers
- 9 people
- Sponsor
- Fukushima Medical University
Non Small Cell Lung Cancer
Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non Small Cell Lung Cancer (NSCLC) - A Feasibility Study
This study is for patients having a course of chest radiotherapy treatment after receiving chemotherapy for the treatment of non-small cell lung cancer.
- Trial name
- Isotoxic-IMRT (NCT01836692)
- Testing
- Intensity Modulated Radiotherapy treatment
- Where
- 7 sites in United Kingdom
- Volunteers
- 38 people
- Sponsor
- Prof Corinne Faivre-Finn
Kidney Cancer
Sunitinib Before or After Surgery in Treating Patients With Metastatic Kidney Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00626509
- Testing
- sunitinib malate, adjuvant therapy, neoadjuvant therapy
- Where
- Italy
- Volunteers
- 110 people
- Sponsor
- Gruppo Italiano Carcinoma Renale
Metastatic Breast Cancer, Lobular Breast Carcinoma
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
This is a prospective observational registry for patients with invasive lobular carcinoma (ILC) of the breast. After the first 1cohort is enrolled, the collected data will be utilized to develop an ILC specific response…
- Trial name
- NCT05964504
- Testing
- Blood Specimen
- Where
- 4 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of California, San Francisco
Nasopharyngeal Carcinoma
Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.
This is an open-label, single center, non-randomized, phase I trial to evaluate the safety and efficacy of gemcitabine combined with apatinib and toripalimab in patients with the recurrent or metastatic nasopharyngeal carcinoma.
- Trial name
- NCT04073784
- Testing
- Gemcitabine combined with Aptinib and Toripalimab
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Sun Yat-sen University
Neoplasms
A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin.
- Trial name
- NCT00264433
- Testing
- ADH -1 (Exherin™)
- Where
- 11 sites in United States, Canada
- Sponsor
- Adherex Technologies, Inc.
Squamous Cell Carcinoma, the Nasal Cavity
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
This is a single arm phase II study that will evaluate the combination of pembrolizumab, docetaxel, and cisplatin or carboplatin (PDC) as single treatment modality in patients with stage II-IVb (T2-4, any N, M0) squamous cell…
- Conditions
- Squamous Cell Carcinoma, the Nasal Cavity, Paranasal Sinuses
- Trial name
- NCT05027633
- Testing
- Pembrolizumab, Docetaxel, Cisplatin
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Thyroid Gland Anaplastic Carcinoma
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
This randomized phase II trial studies the side effects and how well intensity-modulated radiation therapy (IMRT) and paclitaxel with or without pazopanib hydrochloride works in treating patients with anaplastic thyroid cancer.
- Trial name
- NCT01236547
- Testing
- Intensity-Modulated Radiation Therapy, Paclitaxel, Pazopanib Hydrochloride
- Where
- 130 sites in United States
- Volunteers
- 123 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Colorectal Carcinoma
Microsatellite Instability in Colorectal Cancers
In this study, we aimed to identify the different histopathological features of tumors with microsatellite instability (MSI) compared to microsatellite stable (MSS) in patients who underwent surgery for colorectal cancer.
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Microsatellite Instability High, Microsatellite Instability Low
- Trial name
- MSI-CRC (NCT05162248)
- Testing
- Microsatellite instability analysis
- Where
- Turkey (Türkiye)
- Volunteers
- 231 people
- Sponsor
- Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Pulmonary Sarcomatoid Carcinoma, Non-small Cell Lung Cancer
Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma
This study aimed to evaluate the efficacy and safety of first-line Toripalimab combined with bevacizumab, nab-paclitaxel and carboplatin in the treatment of patients with advanced pulmonary sarcomatoid carcinoma.
- Conditions
- Pulmonary Sarcomatoid Carcinoma, Non-small Cell Lung Cancer, Lung Diseases, Thoracic Neoplasms
- Trial name
- NCT04725448
- Testing
- Toripalimab, Bevacizumab, Nab-paclitaxel
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Prostate Cancer
Hormone Therapy in Treating Patients With Advanced Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using triptorelin may fight prostate cancer by reducing the production of androgens.
- Trial name
- NCT00003026
- Testing
- bicalutamide, flutamide, triptorelin
- Where
- 17 sites in Belgium, Israel and 5 more
- Volunteers
- 966 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Small Cell Lung Cancer
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
At this point in the treatment of extensive stage SCLC, we have reached a plateau in survival with conventional chemotherapy and newer regimens are greatly needed.
- Trial name
- NCT00613626
- Testing
- Cisplatin, Etoposide, ZD6474
- Where
- 19 sites in United States
- Volunteers
- 74 people
- Sponsor
- Hoosier Cancer Research Network
Stage III Non-small Cell Lung Cancer
Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer
This is a prospective multi-center randomized clinical trial designed to demonstrate that daily online adaptive radiotherapy with concomitant chemotherapy for stage III non-small cell lung cancer (NSCLC) will result in decreased…
- Trial name
- ARTIA-Lung (NCT05488626)
- Testing
- Adaptive Radiotherapy, Non-Adaptive Radiotherapy, Chemotherapy
- Where
- United States
- Sponsor
- Varian, a Siemens Healthineers Company
Unresectable Hepatocellular Carcinoma
Himalaya Early Access Program
To provide early access (i.e., before marketing authorisation) to tremelimumab 300 mg IV administered once on Day 1 of Cycle 1 plus durvalumab 1500 mg IV followed by durvalumab 1500 mg IV Q4W monotherapy in patients with…
- Trial name
- NCT05345678
- Testing
- Durvalumab, Tremelimumab
- Where
- 4 sites in United States
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.